Indeed, adiponectin analogs are now considered one of the promising new therapeutic targets for obesity-linked hyperglycemia, that mitigates obesity and improves insulin sensitivity [4]. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.